Načítá se...

Successful Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin Retreatment for a Chronic Hepatitis C Genotype 2a Patient Who Relapsed after Sofosbuvir Plus Ribavirin Treatment

The optimum retreatment strategy for chronic hepatitis C virus (HCV) patients who failed directly-acting antiviral agents (DAA)-based therapy is unknown. We herein report the outcomes of an HCV genotype (GT) 2a-infected patient with virologic failure following treatment with sofosbuvir plus ribaviri...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Intern Med
Hlavní autoři: Ishikawa, Toru, Imai, Michitaka, Owaki, Takashi, Sato, Hiroki, Nozawa, Yujiro, Sano, Tomoe, Iwanaga, Akito, Seki, Keiichi, Honma, Terasu, Yoshida, Toshiaki
Médium: Artigo
Jazyk:Inglês
Vydáno: The Japanese Society of Internal Medicine 2018
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6207807/
https://ncbi.nlm.nih.gov/pubmed/29780129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.0621-17
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!